June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Genetics of large pigment epithelial detachment in neovascular age related macular degeneration highlights the role of Complement alternative pathway in this particular phenotype.
Author Affiliations & Notes
  • Alexandra Mouallem
    Ophthalmology department, Hopital Intercommunal de Creteil, Creteil, France
  • Rocio Blanco-Garavito
    Ophthalmology department, Hopital Intercommunal de Creteil, Creteil, France
  • Florence Richard
    INSERM774, Université de Lille Nord de France, INSERM774 Institut Pasteur de Lille, Lille, France
  • Camille JUNG
    Centre de recherche Clinique-Centre de Ressources Biologiques, Hopital Intercommunal de Creteil, Créteil, France
  • Eric H SOUIED
    Ophthalmology department, Hopital Intercommunal de Creteil, Creteil, France
  • Footnotes
    Commercial Relationships   Alexandra Mouallem, None; Rocio Blanco-Garavito, None; Florence Richard, None; Camille JUNG, None; Eric H SOUIED, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1838. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Alexandra Mouallem, Rocio Blanco-Garavito, Florence Richard, Camille JUNG, Eric H SOUIED; Genetics of large pigment epithelial detachment in neovascular age related macular degeneration highlights the role of Complement alternative pathway in this particular phenotype.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1838.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the genetics of variants of patients presenting large neovascular pigment epithelium detachment (PED) resistant to ranibizumab in neovascular age related macular degeneration (nAMD) through a genetic association study.

Methods : Sixty eight patients presenting a large pigment epithelium detachment resistant to ranibizumab (the ARI2 study) are compared to 300 patients presenting unilateral nAMD (the NAT2 study), 1229 patients with exudative nAMD and 444 controls derived from two prospective clinical studies previously published that took place in Hopital Intercommunal de Creteil. nAMD groups were based on visual acuity measurement, fundus examination, treatment response, Spectral Domain Optical Coherence Tomography (SD-OCT) and angiographic data. All samples were genotyped for five single-nucleotide polymorphisms (SNPs) in genes previously associated with AMD: CFH (rs1061170), ARMS2 (rs10490924), C3(rs2230199) and APOE(rs429358 and rs7412) . Significant difference in allele frequency between participants with nAMD and control is the main outcome criteria.

Results : The frequency of the C allele of CFH rs1061170 was significantly higher in the large vascular PED group than in the control group (0.66 vs 0.38, Chi2= 37.23 ; p = 1.01e-09) with an increased frequency in the large neovascular PED group compared to the unilateral nAMD group (0.66 vs 0.55; Chi2 = 5.21; p value = 0,02 ) and to the other nAMD group (0.66 vs 0.52; Chi2 =9.39, p value =0.002). The frequency of the G allele of C3 rs2230199 was also significantly higher compared to the control group (0.74 vs 0.18; Chi2 =177.85 ; p < 2.2e-16), to the unilateral nAMD group (0.74 vs 0.25; Chi2=111.59 p<2.2e-16 ) and to the other nAMD group (0.74 vs 0.25; Chi2= 147.65 p< 2.2e-16). The frequency of the T allele of ARMS2 rs10490924 was significantly higher in the large PED group than in the control group (0.50 vs 0.22; Chi2=49.447; p value= 2.03e-12) but no difference was found with other nAMD groups.

Conclusions : The C allele of CFH rs1061170 and the G allele of C3 rs2230199, known as susceptibility risk alleles of AMD, are associated to the particular phenotype of large neovascular PED resistant to ranibizumab. Other prospective genetic studies should analyze the role of other Complement alternative pathway factors.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×